Offers
bcr-abl-philadelphia-cromosome-quantitative

ABL - Philadelphia Chromosome Quantitative

The BCR/ABL - Philadelphia Chromosome (IS - International Scale) Quantitative test is a crucial diagnostic and monitoring tool in the field of hematology, especially concerning Chronic Myeloid Leukemia (CML). The test is intended to detect and measure the BCR-ABL1 fusion gene that results from a specific chromosomal abnormality known as the Philadelphia chromosome.

CML is a slow-growing blood cancer that originates in the bone marrow, causing excessive growth of white blood cells. It is typically associated with the presence of the Philadelphia chromosome, a mutation that leads to the formation of the BCR-ABL1 fusion gene. This gene is responsible for promoting uncontrolled cell division, leading to the symptoms of CML. Understanding the quantitative measurement of this gene plays a significant role in the diagnosis, treatment, and monitoring of CML.


  • Test Name BCR/ABL - Philadelphia Chromosome (IS - International Scale) Quantitative
  • Sample Type Blood
  • Preparations Required No special preparation is needed for this test.
  • Report Time 3 days

This test utilizes real-time quantitative PCR (polymerase chain reaction) to detect and measure the BCR-ABL1 fusion gene in the blood or bone marrow. The results are reported on an International Scale (IS), which allows for standardization and comparability of results across different laboratories worldwide.

The test is essential not only for confirming the diagnosis of CML but also for monitoring the patient's response to treatment. Depending on the reduction of the BCR-ABL1 gene level over time, doctors can assess whether a patient is responding well to treatment or if a change in therapeutic strategy is required.

Home Sample Collection Process
1
Book your convenient slot
Book your convenient slot
2
Sample Collection by Phlebotomist
Sample Collection by Phlebotomist
3
Reporting of the sample at lab
Reporting of the sample at lab
4
Download Reports
Download Reports
Frequently Asked Questions

This test is typically ordered when CML is suspected based on symptoms, complete blood count results, and bone marrow examination. It is then repeated periodically to monitor the disease progression and response to treatment.

The test uses real-time quantitative PCR to amplify and detect the BCR-ABL1 fusion gene in a sample of the patient's blood or bone marrow. The amount of BCR-ABL1 gene present is compared to a control gene to calculate the ratio, which is then reported on an International Scale (IS).

The results show the level of the BCR-ABL1 fusion gene in the patient's sample. A high level suggests the presence of CML. The level of this gene should decrease with effective treatment. A failure for the levels to decrease or a sudden increase might suggest resistance to treatment.

The test requires a sample of the patient's blood or bone marrow.

Various factors can affect the results, including sample quality, stage of the disease, and the method of testing. The presence of other genetic mutations may also influence the BCR-ABL1 gene level.

If the test results are abnormal, it suggests the presence of CML or resistance to the current treatment. Your doctor will discuss the results with you and suggest the next steps, which might include changes in treatment or further investigations.

Blood collection is usually a simple procedure with minor discomfort. However, bone marrow collection is more invasive and can cause temporary pain or discomfort.

The frequency of the test depends on various factors such as the stage of the disease and the response to treatment. Your doctor will advise you based on your individual condition.

No special precautions are necessary before or after the test. You can continue with your regular activities unless your doctor advises otherwise.

You should consult a hematologist or oncologist if the test results are abnormal. They can provide further guidance and treatment options based on your specific condition.

The BCR/ABL - Philadelphia Chromosome (IS - International Scale) Quantitative test is an indispensable tool in the diagnosis and management of Chronic Myeloid Leukemia. The test, by quantifying the level of the BCR-ABL1 fusion gene, can guide the doctor in understanding the stage of the disease, planning the treatment strategy, and monitoring the response to treatment. Always remember, effective communication with your doctor is the cornerstone of good health.

BCR/ABL - Philadelphia Chromosome (IS - International Scale) Quantitative
₹ 5950
Book Your Slot
Locations Near You in Hyderabad
  • 4KM from Madhapur
  • 3KM from Banjara Hills
  • 1.9KM from Yusufguda
  • 3KM from Madhura Nagar
  • 5KM from Shaikpet